risedronic acid has been researched along with dinoprostone in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jee, WS; Ke, HZ; Kimmel, DB; Tang, LY | 1 |
| Jee, WS; Ke, HZ; Lin, BY; Ma, YF | 1 |
| Huang, LF; Jee, WS; Ke, HZ; Li, QN; Liang, NC; Ma, YF; Xie, H | 1 |
| Chen, YY; Ijiri, K; Jee, WS; Ke, HZ; Ma, Y | 1 |
| Chen, HK; Jee, WS; Li, XJ; Ma, YF; McOsker, JE; Pan, Z | 1 |
| Jee, WS; Li, XJ; Ma, YF; McOsker, JE; Pan, Z | 1 |
| Jee, WS; Li, XJ; Liang, HH; Ma, YF; McOsker, JE; Pan, Z; Setterberg, RB | 1 |
| Chen, YY; Jee, WS; Ke, HZ; Li, XJ; Lin, BY; Lin, CH; Ma, YF | 1 |
| Chen, H; Jee, WS; Li, XJ; Liang, HH; Lin, CH; Ma, YF; Pan, Z; Pun, S | 1 |
| Appleman, S; Keelan, M; Thomson, AB; Wallace, JL | 1 |
1 trial(s) available for risedronic acid and dinoprostone
| Article | Year |
|---|---|
Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Biopsy, Needle; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Gastric Juice; Gastric Mucosa; Gastroscopy; Humans; Interleukin-1; Interleukin-13; Interleukin-8; Middle Aged; Postmenopause; Reference Values; Risedronic Acid; Sensitivity and Specificity; Single-Blind Method | 2003 |
9 other study(ies) available for risedronic acid and dinoprostone
| Article | Year |
|---|---|
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Dinoprostone; Etidronic Acid; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1992 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channel Blockers; Dinoprostone; Disease Models, Animal; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Muscle, Skeletal; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Risedronate pretreatment does not hamper the anabolic effects of prostaglandin E2 in ovx rats.
Topics: Aging; Animals; Dinoprostone; Drug Evaluation, Preclinical; Drug Interactions; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Reference Values; Risedronic Acid; Tibia | 1995 |
Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats.
Topics: Aging; Animals; Body Weight; Bone Development; Bone Diseases, Metabolic; Dinoprostone; Drug Therapy, Combination; Etidronic Acid; Factor Analysis, Statistical; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1995 |
Intermittent treatment of prostaglandin E2 with risedronate is more anabolic than prostaglandin E2 alone in the proximal tibial metaphysis of ovariectomized rats.
Topics: Analysis of Variance; Animals; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Intermittent treatments of prostaglandin E2 plus risedronate and prostaglandin E2 alone are equally anabolic on tibial shaft of ovariectomized rats.
Topics: Animals; Bone Development; Bone Marrow; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Dinoprostone; Disease Models, Animal; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Prostaglandin E2 (PGE2) and risedronate was superior to PGE2 alone in maintaining newly added bone in the cortical bone site after withdrawal in older intact rats.
Topics: Age Factors; Aging; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Etidronic Acid; Female; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1997 |
Intermittent on/off prostaglandin E2 and risedronate are equally anabolic as daily PGE2 alone treatment in cortical bone of ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcium Channel Blockers; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Osteoporosis; Ovariectomy; Ovary; Oxytocics; Rats; Rats, Sprague-Dawley; Risedronic Acid; Time Factors; Weight Gain | 1997 |